Omaveloxolone: An activator of Nrf2 for the treatment of Friedreich's ataxia.

Overview
Research
Identity
Additional Document Info
View All

authors

Profeta, Victoria
McIntyre, Kellie
Wells, McKenzie
Park, Courtney
David Lynch, MD, PhD

publication date

January 1, 2023

published in

Expert opinion on investigational drugs Journal

has subject area